Quantum BioPharma Ltd (fra:0K91) Share Price

Company Profile

Business description
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Contact
1 Adelaide Street East
Suite 801
TorontoONM5C 2V9
CAN
T: +1 416 854-8884
https://www.quantumbiopharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7

Recommended

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.

Tom Lauricella | 19 June 2026

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.

Brian Colello, CPA | 19 June 2026

Most Australians will end up owning SpaceX — whether they like it or not.

Tyger Fitzpatrick | 19 June 2026

Index	Last price	Change	% Change
All Ordinaries	9,047.30	25.90	-0.29%
CAC 40	8,421.14	46.84	-0.55%
DAX 40	24,985.82	40.98	-0.16%
Dow JONES (US)	51,564.70	72.15	0.14%
FTSE 100	10,363.27	36.43	-0.35%
HKSE	23,924.81	387.35	-1.59%
NASDAQ	26,517.93	496.28	1.91%
Nikkei 225	71,250.06	196.57	0.28%
NZX 50 Index	13,535.25	39.62	0.29%
S&P 500	7,500.58	80.48	1.08%
S&P/ASX 200	8,828.70	27.90	-0.32%
SSE Composite Index	4,090.48	17.59	-0.43%